Reset filter
Keywords
Clinical Trial ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

1983 Search results.
Relevance Rating New first Old first

Eligibility Symptomatic Venous Thromboembolism NCT01567917

- 1/22/19 - 1 form, 2 itemgroups, 8 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Incidence of Venous Thromboembolism Following Surgery in Patients With Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01567917

Eligibility Venous Thromboembolism NCT01119261

- 1/4/16 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol; ODM derived from: https://clinicaltrials.gov/show/NCT01119261

Eligibility Venous Thromboembolism Warfarin NCT01119300

- 10/10/18 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin; ODM derived from: https://clinicaltrials.gov/show/NCT01119300 Sponsor: Utrecht Institute for Pharmaceutical Sciences Collaborators: Utrecht University Leiden University Medical Center Erasmus Medical Center University of Ulm Newcastle University University of Liverpool LGC Limited Uppsala University Democritus University of Thrace Elisabethinen Hospital Information provided by (Responsible Party): Anke-Hilse Maitland-van der Zee, Utrecht Institute for Pharmaceutical Sciences Principal Investigator: Munir Pirmohamed, MD PhD University of Liverpool

Eligibility Pulmonary Arterial Hypertension NCT00709956

- 9/27/21 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Iloprost Power 15 in Pulmonary Arterial Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT00709956

Eligibility Pulmonary Arterial Hypertension NCT00617305

- 9/27/21 - 1 form, 1 itemgroup, 17 items, 1 language
Itemgroup: Criteria
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1); ODM derived from: https://clinicaltrials.gov/show/NCT00617305

Eligibility Pulmonary Arterial Hypertension NCT02032836

- 9/17/21 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Comparative PK PD Study in PAH Patients (Fox vs. I-Neb); ODM derived from: https://clinicaltrials.gov/show/NCT02032836

Eligibility Pulmonary Arterial Hypertension NCT02234141

- 9/17/21 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
GS-4997 in Adults With Pulmonary Arterial Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT02234141

Eligibility Pulmonary Arterial Hypertension NCT01841762

- 6/23/21 - 1 form, 2 itemgroups, 28 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
SYMPHONY: A Study of Macitentan in Pulmonary Arterial Hypertension to Validate the PAH-SYMPACT; ODM derived from: https://clinicaltrials.gov/show/NCT01841762

Eligibility Suspected Arterial Hypertension NCT01278732

- 4/19/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Central Blood Pressure Over 24 Hours (ABPM) and Left Ventricular Mass; ODM derived from: https://clinicaltrials.gov/show/NCT01278732

Eligibility Venous Thromboembolism (VTE) Phenprocoumon NCT01119274

- 10/10/18 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon; ODM derived from: https://clinicaltrials.gov/show/NCT01119274 Sponsor: Utrecht Institute for Pharmaceutical Sciences Collaborators: Utrecht University Leiden University Medical Center Erasmus Medical Center University of Ulm Newcastle University University of Liverpool LGC Limited Uppsala University Democritus University of Thrace Elisabethinen Hospital Information provided by (Responsible Party): Anke-Hilse Maitland-van der Zee, Utrecht Institute for Pharmaceutical Sciences

Eligibility Pulmonary Arterial Hypertension NCT02516722

- 6/26/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
TReatment Of Pulmonary HYpertension 1 Study; ODM derived from: https://clinicaltrials.gov/show/NCT02516722

Eligibility Pulmonary Arterial Hypertension NCT02080533

- 6/25/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT02080533

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial